In routine practice, a 0.5% or 1% concentration of foam sclerosant is preferred for vessels less than 5 mm in diameter, while 2% and 3% concentrations are used for vessels larger than 5 mm in diameter. In one ex-vivo study they were unable to demonstrate any statistically significant results among different foam concentrations on 5-10 mm diameter vessels in terms of pathological damage. However, due to the near significant difference between the outcomes of 0.5% and 1% foam sclerosants, the use of 1% foam sclerosant instead of 0.5% may be preferable. Again, 1% foam sclerosant may be preferred to 2% or 3% in larger vessels, as it exerts more severe damage on the vein wall. Further studies are necessary to validate these findings. We have been using the 1% sclerosant for vessels between 5 -10 mm diameters for the past few years without significant recanalizaiton or residual varicosities. Axial veins seem to be more resistant to obliteration by the sclerotherapy compared to the tributaries in clinical practice.
This information is for the medical people who are interested in the vascular disorders.
Saturday, July 05, 2014
Tuesday, June 10, 2014
Compression Therapy Versus Surgery in the Treatment of Patients with Varicose Veins: A RCT, effect on HR QoL?
Varicose veins are common in the people in population groups. Many of them are afraid of operations and at the same time they do not want go for the stockings in the tropical countries. Some of them work in the wet surroundings and they would like to avoid the stockings and compression bandages. Some of them are keen to undergo interventional therapies but they are too expensive ( RF ablation/ Laser) for them. Some times they don't like to undergo surgical treatment after knowing about the recurrence rates.
So, the question before them would be - which is one is better to opt for, stockings or varicose vein interventional therapies? In one study of two year follow up - it was observed that -
At 2 years, 70/76 patients in the surgery group and 11/77 patients in the compression group had been operated on. VCSS-S decreased from 4.6 to 3.5 in the compression group (p < .01) and from 4.8 to 0.6 in the surgery group (p < .001). VSDS decreased from 7.7 to 7.0 in the compression group and from 8.2 to 0.9 in the surgery group (p < .0001). HRQoL did not change in the compression group, but improved significantly in the surgery group. It was concluded that - The surgical elimination of non-complicated superficial venous reflux is an effective treatment when compared with providing compression stockings only.
HRQoL did not change in the compression group, but improved significantly in the surgery group.
So, the question before them would be - which is one is better to opt for, stockings or varicose vein interventional therapies? In one study of two year follow up - it was observed that -
At 2 years, 70/76 patients in the surgery group and 11/77 patients in the compression group had been operated on. VCSS-S decreased from 4.6 to 3.5 in the compression group (p < .01) and from 4.8 to 0.6 in the surgery group (p < .001). VSDS decreased from 7.7 to 7.0 in the compression group and from 8.2 to 0.9 in the surgery group (p < .0001). HRQoL did not change in the compression group, but improved significantly in the surgery group. It was concluded that - The surgical elimination of non-complicated superficial venous reflux is an effective treatment when compared with providing compression stockings only.
HRQoL did not change in the compression group, but improved significantly in the surgery group.
http://www.ejves.com/article/S1078-5884(14)00096-3/abstract
Pinjala R K
Monday, June 09, 2014
Home therapy for Acute DVT in the leg! Is it safe in all countries?
Home therapy for DVT is convenient and it gives freedom with safety to treat the patients coming in the out patient clinic without admission in to the hospitals and additional burden hospital beds and expenditure to the family.
In patients with DVT, home treatment was associated with a better outcome than treatment in the hospital. Current guidelines of antithrombotic therapy recommend initial treatment of patients with acute deep venous thrombosis (DVT) with low-molecular-weight heparin (LMWH), fondaparinux, or unfractionated heparin (UFH) over no such initial therapy.1 A number of studies comparing LMWH administered at home (without hospital admission or after early discharge) with UFH in the hospital suggested that home therapy may be associated with improved outcome and better quality of life.2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 Hence, in DVT patients with adequate home circumstances, current guidelines recommend that most patients with DVT be initially treated at home rather than in the hospital.1 However, many physicians are still concerned about the safety of home therapy because even with adequate anticoagulation, some patients may present with symptomatic pulmonary embolism (PE), recurrent DVT, major bleeding complications, or even death.
The RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) registry is an ongoing, international (Spain, France, Italy, Israel, Germany, Switzerland, Republic of Macedonia, and Brazil), multicenter, prospective registry of consecutive patients presenting with symptomatic acute venous thromboembolism (VTE). It started in Spain in 2001, and some years later, the database was translated into English to expand the Registry to other countries, with the aim to help physicians worldwide select the most appropriate therapy for their patients. Data from this registry have been used to evaluate outcomes after acute VTE, such as the frequency of recurrent VTE, major bleeding, and mortality, and risk factors for these outcomes.13, 14,15 and 16 The current analysis compared the outcome of outpatients with acute DVT of the lower limbs within the first week of anticoagulation according to initial therapy at home or in the hospital.
References
1. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, S.Z. Goldhaber et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141 (Suppl) (2012), pp. e419S–e494S
2. M. Bakker, P.J. Dekker, E.A. Knot, P.F. van Bergen, J.J. Jonker Home treatment for deep venous thrombosis with low-molecular-weight heparinLancet, 2 (1988), p. 11423. M. Levine, M. Gent, J. Hirsh, J. Leclerc, D. Anderson, J. Weitz et al.A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med, 334 (1996), pp. 677–681
4.M.M. Koopman, P. Prandoni, F. Piovella, P.A. Ockelford, D.P. Brandjes, J. van der Meer et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The TASMAN Study Group N Engl J Med, 334 (1996), pp. 682–687
5. I.G. Schraibman, A.A. Milne, E.M. Royle Home versus in-patient treatment for deep vein thrombosisCochrane Database Syst Rev, 2 (2001), p. CD003076
6. R. Othieno, M. Abu Affan, E. Okpo Home versus in-patient treatment for deep vein thrombosisCochrane Database Syst Rev, 3 (2007), p. CD003076
7. W. Ageno, R. Grimwood, S. Limbiati, F. Dentali, L. Steidl, P.S. Wells Home-treatment of deep vein thrombosis in patients with cancer Haematologica, 90 (2005), pp. 220–224
8. S. Siragusa, C. Arcara, A. Malato, R. Anastasio, M.R. Valerio, F. Fulfaro et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients Ann Oncol, 16 (Suppl 4) (2005), pp. 136–139
9. S.R. Kahn, V. Springmann, S. Schulman, J. Martineau, J.A. Stewart, N. Komari et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost, 108 (2012), pp. 493–498
10. M. Winter, D. Keeling, F. Sharpen, H. Cohen, P. Vallance, Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology Procedures for the outpatient management of patients with deep venous thrombosis. Clin Lab Haematol, 27 (2005), pp. 61–66
11. V. Snow, A. Qaseem, P. Barry, E.R. Hornbake, J.E. Rodnick, T. Tobolic, American College of Physicians; American Academy of Family Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med, 146 (2007), pp. 204–210
12. J.D. Douketis. Treatment of deep vein thrombosis. What factors determine appropriate treatment?Can Fam Physician, 51 (2005), pp. 217–223
Sunday, May 18, 2014
Oncolytic viruses
Oncolytic viruses are providing an interesting approach to treat cancers:
Some time
back in the past, we postulated that the virus may cause the some types of cancers.
But today we are postulating that viruses can be used to cure the cancers. Cancers
tend to grow at the expense of the normal tissues and so are the viruses when
they invade the body. Now, there are attempts to engineer the viruses to do the
jobs favorable for the humans beings and that seems to be good. Some have engineered
viruses to cure multiple myeloma and others are using the virus loaded stem
cells to treat tumors. Recently herpes virus loaded stem cells are used to
treat brain tumor (in mice) such as glioblastoma multiforme which is a
difficult tumor to treat. It said that “Further
preclinical work will be needed to use the herpes-loaded stem cells for breast,
lung and skin cancer tumours that metastasize to the brain. Shah predicts the
approach will enter clinical trials within the next two to three years”.
Monday, January 27, 2014
What is CaVenT study?
Long-term outcome after additional catheter-directed thrombolysis versus
standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT
study): a randomised controlled trial.
209 patients were randomly
assigned to treatment groups (108 control, 101 CDT). At completion of 24
months' follow-up, data for clinical status were available for 189 patients
(90%; 99 control, 90 CDT). At 24 months, 37 (41·1%, 95% CI 31·5—51·4) patients
allocated additional CDT presented with PTS compared with 55 (55·6%, 95% CI
45·7—65·0) in the control group (p=0·047). The difference in PTS corresponds to
an absolute risk reduction of 14·4% (95% CI 0·2—27·9), and the number needed to
treat was 7 (95% CI 4—502). Iliofemoral patency after 6 months was reported in
58 patients (65·9%, 95% CI 55·5—75·0) on CDT versus 45 (47·4%, 37·6—57·3) on
control (p=0·012). 20 bleeding complications related to CDT included three
major and five clinically relevant bleeds.
from University of Oslo.
Longterm outcomes after catheter directed thrombolysis in DVT
What
is CaVenT study?
Long-term outcome after additional catheter-directed thrombolysis versus
standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT
study): a randomised controlled trial. 209 patients were randomly
assigned to treatment groups (108 control, 101 CDT). At completion of 24
months' follow-up, data for clinical status were available for 189 patients
(90%; 99 control, 90 CDT). At 24 months, 37 (41·1%, 95% CI 31·5—51·4) patients
allocated additional CDT presented with PTS compared with 55 (55·6%, 95% CI
45·7—65·0) in the control group (p=0·047). The difference in PTS corresponds to
an absolute risk reduction of 14·4% (95% CI 0·2—27·9), and the number needed to
treat was 7 (95% CI 4—502). Iliofemoral patency after 6 months was reported in
58 patients (65·9%, 95% CI 55·5—75·0) on CDT versus 45 (47·4%, 37·6—57·3) on
control (p=0·012). 20 bleeding complications related to CDT included three
major and five clinically relevant bleeds.
from University of Oslo.
Transplantation of an allogeneic vein bioengineered with autologous stem cells
Vein segments are harvested and used for bypassing the arterial occlusions and these vein grafts have good long term patency. But when a vein has to be bypassed then we do not have an ideal graft available to us. In the recent past a 9 cm segment of allogeneic donor iliac vein was decellularised and subsequently recellularised with endothelial and smooth muscle cells differentiated from stem cells obtained from the bone marrow of the recipient. Such a graft may not require suppression for life time by sweedish team of doctors.
After one year a second stem-cell populated vein graft was used for relieving the compression of first graft graft and to lengthen the previous graft which was used for replacing the portal vein in a patient with extra hepatic portal vein obstruction. With restored portal circulation the patient has substantially improved physical and mental function and growth. The patient has no anti-endothelial cell antibodies and is receiving no immunosuppressive drugs. An acellularised deceased donor vein graft recellularised with autologous stem cells can be considered for patients in need of vascular vein shunts without the need for immunosuppression.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60633-3/fulltext#article_upsell
Sunday, January 26, 2014
Robert B. Rutherford 29 July 1931–22 November 2013
Bob Rutherford, for more than three decades, was arguably the best known and most respected vascular surgeon in the world. His textbook, VASCULAR SURGERY, has been “the textbook” and remains the premier source of information in the field since it first appeared in 1976. Since then, Rutherford's text gained in authority and respect as it went through its subsequent eight editions, just as vascular surgery grew and morphed into the defined specialty it is today. In 1996, Bob received an Honorary Fellowship from the Royal College of Surgeons and he delivered the prestigious Lister Lecture in Glasgow, Scotland. In 2005, Bob received the singular honor of the SVS Lifetime Achievement Award and, in 2006, he received the Julius H. Jacobson II Physician Excellence Award from the Vascular Disease Foundation for his exceptional leadership and contributions to vascular disease education and management.
Thursday, January 23, 2014
Buerger's Disease - is still unresolved in Asian countries?
More than 100 years back the first paper on Buerger's disease was published. In many countries the disease prevalence is significantly reduced. But in the developing and poor countries where childhood smoking is uncontrolled this disease seems to be persistent. The disease is surprisingly less common in urban population and in those who have gone to proper schooling! probably this means these children are protected from the risk of childhood smoking. There are reports mentioning that autoimmunity plays an important role. The initial enthusiasm to do surgeries faded away slowly as the results are universally not satisfactory. Now, a new concept directed towards cell therapies (stem cells) renewed the interest in detecting the patients who can be benefited by them. Here is a report on endothelial progenitor cells and TAO.
Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger’s disease)
Hyung Sub Park1 Kyung Hee Cho1 Koung Li Kim2 Duk-Kyung Kim2Taeseung Lee1
Taeseung Lee Department of Surgery Seoul National University Bundang Hospital Seoul National University College of Medicine 173-82 Gumi-ro, Bundang-gu, Seongnam-si Gyeonggi-do 463-707 Korea Email: tslee@snubh.org
Abstract
To determine the role of endothelial progenitor cells (EPCs) in the pathogenesis of thromboangiitis obliterans (TAO), EPC numbers and colony-forming units, migratory function and tubular structure formation in vitro were compared between 13 young male TAO patients and two age-matched healthy control groups: 11 smokers and 12 non-smokers. TAO patients had significantly lower numbers of EPCs and EPC colonies compared to both non-smokers [190 (97.0–229) vs 528 (380–556), p < 0.001 for EPCs and 0.80 (0.53–1.00) vs 2.80 (2.08–4.00) per mm2, p = 0.001 for EPC colonies] and smokers [190 (97.0–229) vs 272 (229–326), p = 0.012 for EPCs and 0.80 (0.53–1.00) vs 2.80 (1.80–3.93) per mm2, p = 0.001 for EPC colonies]. However, there were no significant differences in migratory function or tube formation between the three groups. These results suggest that TAO patients have an intrinsic decrease in EPCs not entirely associated with smoking, which may be the cause of endothelial dysfunction seen in TAO patients leading to the development of this disease at early ages.
Hyung Sub Park1 Kyung Hee Cho1 Koung Li Kim2 Duk-Kyung Kim2Taeseung Lee1
Taeseung Lee Department of Surgery Seoul National University Bundang Hospital Seoul National University College of Medicine 173-82 Gumi-ro, Bundang-gu, Seongnam-si Gyeonggi-do 463-707 Korea Email: tslee@snubh.org
Abstract
To determine the role of endothelial progenitor cells (EPCs) in the pathogenesis of thromboangiitis obliterans (TAO), EPC numbers and colony-forming units, migratory function and tubular structure formation in vitro were compared between 13 young male TAO patients and two age-matched healthy control groups: 11 smokers and 12 non-smokers. TAO patients had significantly lower numbers of EPCs and EPC colonies compared to both non-smokers [190 (97.0–229) vs 528 (380–556), p < 0.001 for EPCs and 0.80 (0.53–1.00) vs 2.80 (2.08–4.00) per mm2, p = 0.001 for EPC colonies] and smokers [190 (97.0–229) vs 272 (229–326), p = 0.012 for EPCs and 0.80 (0.53–1.00) vs 2.80 (1.80–3.93) per mm2, p = 0.001 for EPC colonies]. However, there were no significant differences in migratory function or tube formation between the three groups. These results suggest that TAO patients have an intrinsic decrease in EPCs not entirely associated with smoking, which may be the cause of endothelial dysfunction seen in TAO patients leading to the development of this disease at early ages.
Sunday, January 12, 2014
How specific are venous symptoms for diagnosis of chronic venous disease?
I feel this is very important to know this fact, before we confirm and treat CVI patients based on only few symptoms. The recently introduced Endovenous ablative therapies are offered to lot of patients due to the safety and ease with which these procedures are performed. It would be useful to base our interventions with adequate supportive clinical features after exclude the other possible conditions. If we take these precautions there will be more satisfaction and improvement therapeutic effectiveness.
Pinjala R K
13th Jan 2014
Pinjala R K
13th Jan 2014
Fruit juice - may be better to avoid concentrated juices!
Some of us like Fruit juices and believe they are safe. But
are they safe?
Dear
NIMS Doctor,
Fruits
and fruit juices are considered to be safe and good for the health by many of
us. Some of us take whole fruit while some prefer to take the readymade fruit
juices. Now there are alerts to avoid the fruit juices and recommendations are
in favour of whole fruit intake. If one would still like to take juices it is
better to dilute them adequately.
Fruit juice
should be removed from the recommended list of five-a-day portions of fruit or
vegetables in the U.K. as it contained as much sugar as many soft drinks, an
adviser to the government on obesity has said. Susan Jebb, head of diet and
obesity research at the Medical Research Council’s Human Nutrition Research
unit in Cambridge, said she did not see juice as a healthy option.
“I would support taking it out of the five-a-day
guidance,” she said. “Fruit juice isn’t the same as intact fruit and it has got
as much sugar as many classical sugar drinks. It is also absorbed very fast so
by the time it gets to your stomach your body doesn’t know whether it’s
Coca-Cola or orange juice, frankly,” she told Sunday Times.
“I have to say it is a relatively easy thing to give up.
Swap it and have a piece of real fruit. If you are going to drink it, you
should dilute it,” she said.
Ms. Jebb said she had herself stopped drinking orange
juice and advised others to do so, or at least drink it diluted.
The paper quoted her as saying she would support a wider
tax on sugar-heavy drinks.
Ms. Jebb works closely with the U.K. government on diet
and obesity issues, and leads the government’s so-called health responsibility
deal, which oversees voluntary pledges by the food and drink industry to
improve public health. Her comments follow a similar warning in September by
two U.S. scientists, Barry Popkin and George Bray, who exposed the health risks
of fructose corn syrup in soft drinks in 2004.
Popkin, a professor of nutrition at the University of
North Carolina, told the Guardian that fruit juices and fruit smoothies were
“the new danger”.
“Think of eating one orange or two and getting filled.
Now think of drinking a smoothie with six oranges and two hours later it does
not affect how much you eat. The entire literature shows that we feel full from
drinking beverages like smoothies but it does not affect our overall food
intake, whereas eating an orange does,” he said. “So pulped-up smoothies do
nothing good for us but do give us the same amount of sugar as four to six
oranges or a large coke. It is deceiving,” Mr. Popkin said.
Wednesday, January 08, 2014
Smoking prevalence among Indian men decreased from 33.8 percent to 23 percent (1980-2012) !
A new research from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington has revealed that India has made progress in reducing the prevalence of daily smoking among men.Smoking is the third top risk for health loss in India, leading to nearly one million deaths each year in the country. Between 1980 and 2012, smoking prevalence among Indian men decreased from 33.8 percent to 23 percent.
According to the research India has more female smokers over 12.1 million than any country except the United States. In 2012, female smoking prevalence was 3.2 percent, which is virtually unchanged since 1980. "Smoking rates remain dangerously high for men and there is more work to be done to drive these rates lower," Dr. Srinath Reddy, President of the Public Health Foundation of India, said in response to the findings. "The high number of female smokers in India is also troubling," he said.These developments in India have taken place against an increasingly complex global backdrop.Trends in age standardized tobacco use vary greatly by country and gender, with places such as Mexico and Canada seeing rapid declines while others, such as Russia and China, seeing increases since 2006.Male smokers continue to outnumber female smokers and, since 1980, the global rate of decline in female smoking prevalence was consistently faster than in men.The study is published in the Journal of the American Medical Association.
Tuesday, January 07, 2014
Can we manage TIA patients safely in outpatient clinics?
Can lower risk patients presenting with transient
ischemic attack be safely managed as outpatients? This is a question we need to
answer during these days, where one would like to avoid hospitalization
expenditure
A paper published by an Australian author said in
conclusion, medical assessment, expedited investigation with immediate
commencement of secondary prevention and outpatient neurology review may be a
reasonable alternative to admission for low risk patients presenting to the
Emergency Department with TIA.
Stroke is second only to ischemic heart disease as
a leading cause of disease burden in Australia. Stroke places considerable
strain on the public health system in Australia (length of stay averages 8 days
and outcomes range from returning home to nursing home placement to death).
There is a paucity of data regarding the best approach to care provision
following a transient ischemic attack (TIA) in the Australian setting. The risk
of stroke following a TIA is as high as 5–10% in the first 7 days depending on
the population and clinical setting examined, with the lowest risks observed in
the context of emergent management. Higher rates have been reported among high
risk populations in the absence of protocol driven initiation of secondary
prevention.
TIA represent a window of opportunity for
effective secondary stroke prevention.7 Review in a daily (as opposed to
weekly) TIA clinic with no appointment necessary and immediate
commencement of therapy has demonstrated an 80% reduction in risk of recurrent
cerebrovascular accident within 90 days (10.3% versus 2.1%) in the EXPRESS
study with demonstrated cost-savings in terms of bed days, acute costs, and 6
month disability.8 Risk reduction with early intervention is also supported by
results of the SOSTIA study and other approaches, all of which involve
immediate commencement of anti platelet therapy.
External validation studies have yielded
inconsistent results with regard to predictability of the age, blood pressure,
clinical features, duration of symptoms and diabetes (ABCD2) score at determining
risk of stroke recurrence, thus, its clinical utility remains unclear. Two
recent large population based studies have again raised questions about the
clinical utility of the ABCD2 score. It is likely that the optimal approach to
risk stratification incorporates the results of diffusion-weighted imaging (as
examined by the more recently devised ABCD2–I and ABCD3–I scores) and early
carotid imaging (as assessed by the ABCD3–I score), although prompt cerebral
MRI may not be possible in many practice settings.
Stroke is a major cause for loss
of life, limbs and speech in India, with the Indian Council of Medical Research
estimating that in 2004, there were 9.3 lakh cases of stroke and 6.4 lakh
deaths due to stroke in India, most of the people being less than 45 years old. Experts say that if deaths as well as disability
are counted together, then India lost 63 lakh of disability-adjusted life years
in 2004.WHO estimates suggest that by 2050, 80% stroke cases in the world would
occur in low and middle income countries mainly India and China. Those with high
blood pressure, diabetes, high blood fat (cholesterol) are specially at risk.
The most important of these risk factors is high BP. In India, more than 16% of
people above 20 years of age suffer from high BP. Fifty per cent of those with
high BP are not even aware of it. Of those who are aware, only 50% take
measures to control it, and of those who take these measures, only 50% are
adequately controlled. "Thus, only 12.5% of patients with high BP are
adequately controlled". In the absence of high risk factors (low
risk patients) one may consider the outpatient clinic protocol based therapies in
India also!!
Cervical rib and thromboembolic stroke
Middle aged, overweight woman was admitted with critical ischemia
in the right upper limb. She was symptomatic for more than a month. In our
clinic (tertiary care hospital) it is uncommon to see patients with history
shorter than 1 week. She required trans brachial thrombectomy (in emergency)
and removal of the cervical rib (elective) and subclavian artery thrombectomy.
The vertebral artery was close to the scalenous anticus muscle. Yet the
thrombus in the subclavian artery rarely goes to the vertebral artery to cause
the thromboembolic stroke. But we never came across such a patient in the last 25 years in our practice. It is possible that the neurologist treating the stroke patient may miss cervical rib, if the patient has not been specifically examined and evaluated.
I came across a paper – where this information was
published, I thought it will be useful to you, if you are looking for this type
of information.
Thoracic outlet syndrome occurs due to compression of the
neurovascular structures as they exit the thorax. Subclavian arterial
compression is usually due to a cervical rib, and is rarely associated
with thromboembolic stroke. The mechanism of cerebral embolization associated
with the thoracic outlet syndrome is poorly understood, but may be due to
retrograde propagation of thrombus or transient retrograde flow within the
subclavian artery exacerbated by arm abduction. We report an illustrative
patient and review the clinical features, imaging findings and management of
stroke associated with thoracic outlet syndrome.
J Clin Neurosci. 2013 Oct 4. pii:
S0967-5868(13)00514-6. doi: 10.1016/j.jocn.2013.07.030. [Epub ahead of print] Thromboembolic
stroke associated with thoracic outlet syndrome. Meumann EM, Chuen J, Fitt G, Perchyonok Y, Pond F, Dewey HM.
Saturday, January 04, 2014
$25 billion is spent annually in the United States treating chronic skin wounds related mostly to poor blood circulation?
The research review team, led by investigators at the Johns Hopkins Evidence-Based Practice Center and the Johns Hopkins Wound Healing Center, noted than an estimated $25 billion is spent annually in the United States treating chronic skin wounds related mostly to poor blood circulation, disorders known as venous ulcers. Their prevalence is rising along with rates of diabetes and obesity, and the review was undertaken in an effort to inform physicians about the treatment options.
Probably we should take them ( tiny and giant ulcerations) more seriously and every effort should be made to prevent them and heal them early. - Pinjala R K
Probably we should take them ( tiny and giant ulcerations) more seriously and every effort should be made to prevent them and heal them early. - Pinjala R K
Tuesday, December 31, 2013
Inelastic compression therapy - Is it superior to elastic compression therapies?
Inelastic versus elastic leg compression in chronic
venous insufficiency – what are the effects on venous hemodynamics
In the venous
disease of the lower limbs, compression therapy is considered as an important component
of the treatment. There are many ways to deliver the compression therapy to the
legs in the venous disease patients. Compression
therapy can treat venous stasis, venous hypertension, and venous edema.
Different methods of compression therapy have been described periodically over
the last 2,000 years. In addition to static compression, specialized
compression pumps have been developed to treat resistant edema. A technique of
massage called manual lymphatic drainage has emerged to treat primary and
secondary lymphedema. Objectives of compression therapy are to reduce the
swollen limb to minimum size, maintain that size, and allow the patient to
participate in the care of his limb whenever possible. Reduction therapy is
achieved by limb elevation, compression pumps as necessary, and compression
wraps. Maintenance therapy largely consists of compression wraps or compression
stockings. Nonelastic devices have found a place in treating severe lymphedema
but it should be emphasized that periodic follow-up must be done during
maintenance therapy so that adjunctive maintenance measures can be added as
needed. In tropical countries under humid conditions people find it difficult
to tolerate the compression therapies unlike those living in the cold
countries. People (farmers) working in the wet fields refuse to wear the compression
bandages. We need to need monitor the compression therapy measures at regular
intervals and make sure that the people regularly apply them.
A brief
history of compression
Descriptions
of limb compression therapy are found in the Corpus Hippocraticum (450-350
BC). Because the Greeks believed that “all wounds, especially those of
the lower limbs, contradict standing, sitting or walking,”
they used compression to counter the adverse effects of gravity and upright
posture. Guy de Chauliac, a French anatomist and surgeon, published the first
mention of compression therapy for varicose veins in Chirurgica magna (1363),
a leading reference textbook for almost four centuries. Giovanni Michele
Savonarola (1440) formalized “conservative treatment” for varicose veins. His Practica describes
how bandages should be started at the distal part of the limb and worked upward
to the proximal portion. Savonarola’s successor at Padua University was
Fabricio d’Aquapendente
(1537-1619), who further refined these bandaging methods. The first description
of laced stockings (made from dog leather) can be found in his De
chirurgicis operationibus. (Contrary to popular belief, this is not the
reason why “going barefoot” came to be known as “airing out your dogs”). William
Harvey’s 17th century description of the circulation of blood
led to an understanding of the physiological rationale for limb compression. By
the latter 18th century, Johann Christian Anton Theden
(1714-1797) was postulating that compression “reduces somewhat the flow of
humours, stimulates the activity of the skin over the suffering areas and
increases the returning flow of humours.”The use of sponges under a
compression device (to apply additional pressure over specific areas) was
introduced by E. Home and others (1797). The need for a bandage that could be
applied by the patient led H.A. Martin in Boston to develop a clothless
bandage made of pure rubber, which could be placed directly atop the skin and
held in place by another bandage. Thomas Baynton advocated adhesive bandages
and promoted their use after they became commercially available toward the end
of the 19th century. The zinc oxide paste dressing, introduced
by P.G. Unna in 1885, is still in use today. Ready-to-use zinc oxide bandages
came onto the market after the First World War (Varicosan, Glauco, Weicosana,
others). Modern elastic stockings were born on October 26, 1948 when William
Brown, of Middlesex, England, submitted a patent for compression hose.
The
first compression pumps were introduced in 1902 when Hofmeister proposed a treatment
for arm edema in which the limb was placed within a metal cylinder filled with
mercury. In 1917, Hartel used an air-filled tube for the same
purpose. Hammersfahr (1931) published his treatment of venous stasis using an
air cushion that filled and emptied rhythmically. Karl Linser developed a
massage boot that utilized an air-filled chamber in which the pressure varied
as the subject walked.
Manual
lymphatic drainage has been used to remove extremity edema for more than 50
years. The original technique used soft massage to stimulate lymphatic vessels
and propel fluid through their channels. Because 20% or more of patients with
chronic venous insufficiency also have a component of lymphedema, manual
lymphatic drainage may have a role in a compression therapy program for chronic
venous insufficiency.
Nonelastic
devices. The Circaid® (see Fig) provides rigid nondistensible resistance to the
limb. It can be applied over a compression stocking for additional compression.
Topical
compression therapy provides a means to treat or prevent these adverse effects.
Limb compression (1) alters the tissue pressure gradient, which reduces edema
formation and increases edema resorption; (2) reduces the caliber of the veins
and increases venous flow velocity; (3) reduces orthostatic reflux, residual
volume, and ambulatory venous pressure (in part, by re-recruiting venous valves
and reducing reflux in the perforating vessels); and (4) improves the
effectiveness of the muscle pump.
Mayberry
et al (1991) - In 16 patients with CVI – compression therapy affect was studied
on – femoral, popliteal vein velocities (duplex scan), reflux and ambulatory
venous pressures direct measurement. Although stocking produced substantial
superficial vein, they produced only modest increases in the popliteal vein
velocity and no significant improvement in deep venous hemodynamics. These
authors analysed another 8 studies (previous) and said the differences in the
findings were due to consistencies in the study designs.
R
K Spence et al (1996 -JVS) found that inelastic compression (see fig Circaid) has
a significant effect on deep venous hemodynamics by decreasing venous reflux
and calf muscle pump function better than compression stockings. They concluded
that initially the superficial reflux should be adequately treated with
stockings. Those with extensive clinical symptoms caused by abnormal deep
venous hemodynamics and primary calf muscle pump dysfunction may benefit more
from the inelastic compression.
Monday, December 30, 2013
Carotid intima media thickness (DCCT/EDIC) long term followup
The Diabetes Control and Complications Trial (DCCT) has documented the profound beneficial effects of intensive diabetes therapy (INT) compared with conventional therapy (CON) on the development and progression of microvascular and neuropathic complications during the DCCT, mediated by the separation of HbA1c levels between the two treatment groups. In addition, the further separation of these outcomes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study, despite the disappearance of the differences in HbA1c seen in the DCCT (metabolic memory), has been described. The long-term benefits of INT versus CON are almost completely explained by the differences between the two groups in the mean level of HbA1c during the mean of 6.5 years of treatment in the DCCT .
They assessed carotid IMT by ultrasonography at EDIC years 1, 6, and 12 . At year 1, the results were largely within the age-matched, nondiabetic range with no difference between the DCCT INT and CON groups. Carotid ultrasonography was again repeated during EDIC year 6. During the ∼5 year period between the two measurements, IMT increased within both groups, significantly more so in the former CON than INT group (Fig. 1). Ultrasonography was again conducted during year 12 (12). IMT increased even more in both groups, consistent with the recognized effects of aging. The magnitude of the increase between EDIC years 6 and 12 was slightly greater in the former INT than in the CON group, but the mean IMT remained significantly less at 12 years in the former INT group.
They assessed carotid IMT by ultrasonography at EDIC years 1, 6, and 12 . At year 1, the results were largely within the age-matched, nondiabetic range with no difference between the DCCT INT and CON groups. Carotid ultrasonography was again repeated during EDIC year 6. During the ∼5 year period between the two measurements, IMT increased within both groups, significantly more so in the former CON than INT group (Fig. 1). Ultrasonography was again conducted during year 12 (12). IMT increased even more in both groups, consistent with the recognized effects of aging. The magnitude of the increase between EDIC years 6 and 12 was slightly greater in the former INT than in the CON group, but the mean IMT remained significantly less at 12 years in the former INT group.
Saturday, December 28, 2013
NETs and Deep vein thrombosis
Deep vein thrombosis (DVT) is a major health problem that requires improved prophylaxis and treatment.Inflammatory conditions such as infection, cancer, and autoimmune diseases are risk factors for DVT. We and othershave recently shown that extracellular DNA fibers produced in inflammation and known as neutrophil extracellulartraps (NETs) contribute to experimental DVT. NETs stimulate thrombus formation and coagulation and are abundant inthrombi in animal models of DVT. It appears that, in addition to fibrin and von Willebrand factor, NETs represent a third
thrombus
scaffold. Here, we review how NETs stimulate thrombosis and discuss
known and potential interactions ofNETs with endothelium, platelets, red
blood cells, and coagulation factors and how NETs could influence
thrombolysis.It was proposed that drugs that inhibit NET formation or facilitate NET degradation may prevent or treat DVT.
Deep vein thrombosis (DVT) is a debilitating disease that may
be complicated by pulmonary embolism (PE). Together DVT and PE are designated
as venous thromboembolism. In the United States, venous thromboembolism develops
in an estimated 900000 patients each year, and PE is responsible for ≈300000
deaths, which exceeds the mortality from myocardial infarction or stroke.DVT
complications, in addition to PE, include post thrombotic syndrome caused by chronic
venous stasis even in the absence of active thrombosis
NETs are
produced to allow neutrophils to trap and disarm microbes in the extracellular
environment. NETs are scaffolds of intact chromatin fibers with antimicrobial
proteins, ideal to retain large quantities of microbes. Therefore, some
pathogenic bacteria have evolved to express an extracellular deoxyribonuclease
(DNase), which dismantles NETs and promotes virulence. Extracellular traps are
formed in humans, animals, and even plants, indicating that NETs provide an
evolutionary conserved protective mechanism.
NETs
formation is not restricted to neutrophils, and different cell types use
different cellular mechanisms to release extracellular trap. One mechanism used
by human neutrophils is NETosis. NETosis is a multistep cell death program . On
activation, certain enzymes translocate from the granules to the nucleus.
Histones are degraded by neutrophil elastase (NE) and citrullinated by
peptidylarginine deiminase 4 to unwind chromatin. Further hallmarks are the
breakdown of granular and nuclear membranes and cytolysis as the final step in
NETosis.
Implications
of NETs in Thrombolysis -To degrade and solubilize thrombi to restore blood flow, fibrin
and VWF as the main scaffolds need to be proteolytically fragmented by
the proteases plasmin and a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13, respectively. NETs are newly
recognized third scaffolds that need to be undone during thrombolysis (Figure
1C). NETs were seen to colocalize with fibrin in clots 15 and with VWF in
venous thrombi. In vitro, we could show that NETs provide a scaffold for blood
clots that is resistant to tPA-induced thrombolysis. We incubated recalcified
blood with neutrophils which were prestimulated to release NETs. As shown in
Figure 3, after filtration, blood clots appeared in control samples and
tPA- or DNase-treated blood but not in blood treated with the combination of
tPA and DNase. Immunostainings revealed that in the presence of tPA, blood
clots lacked fibrin and were held together by a scaffold of extracellular
DNA (Figure 3B). DNase1 is the predominant nuclease in plasma. Interestingly,
the plasminogen system cooperates with DNase1 during chromatin degradation.
DNase1 has only limited activity to degrade chromatin because it preferentially
degrades protein-free DNA. Plasminogen, activated by either tPA or urokinase-type
plasminogen activator, degrades histones and therefore allows for degradation
of DNA by DNase1. Monocytes/macrophages may also support the DNA degradation
because their lysosomes contain DNase2, which is important for the removal of
apoptotic cells (Figure 1C). NETs and fibrin degradation by plasmin and DNase
could result in the simultaneous release of DNA and fibrin fragments. In
baboon DVT, plasma DNA increases with similar kinetics to the fibrin
degradation product D-dimers. Recently, in collaboration with Thomas
Wakefield’s group, we found increased levels of DNA in plasma from patients
with DVT compared with healthy controls and symptomatic patients who did not
have DVT. Here also, plasma DNA con-centrations correlated with D-dimers
(unpublished data; Diaz and Fuchs, 2012). Therefore, it is plausible that
circulating DNA may reflect the degradation of NETs within a thrombus.NETs may
also promote thrombolysis. In vitro studies have shown that NE and cathepsin G
can degrade fibrin, and these proteases are present on NETs and could enhance
fibrinolysis in DVT. In addition, NETs may also recruit plasminogen from the
plasma. Histone H2B can serve as a receptor for plasminogen on the surface of
human monocytes/macrophages and perhaps could do so in NETs.
Subscribe to:
Posts (Atom)







